Zelgen(SH:688266) Xin Lang Cai Jing·2025-09-11 07:45Core Viewpoint - The company announced that clinical research data and latest progress for its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will be presented at the CSCO Annual Meeting from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Data - ZG006 has shown promising results in a Phase II dose-optimization clinical study for patients with refractory advanced small cell lung cancer, with a total of 60 patients included in the analysis as of May 12, 2025 [1] - The best overall response rates (ORR) for the 10 mg Q2W and 30 mg Q2W groups were 60.0% and 63.3% respectively, with confirmed response rates of 53.3% for both groups [1] - Disease control rates (DCR) were reported at 73.3% for the 10 mg Q2W group and 70.0% for the 30 mg Q2W group [1] Group 2: ZG005 Clinical Data - ZG005, in combination with Etoposide and Cisplatin, has been evaluated in a Phase I/II clinical study for first-line treatment of advanced neuroendocrine carcinoma, with 84 patients enrolled as of August 21, 2025 [1] - Among the 60 patients who could be assessed for efficacy, the ORR was reported at 43.8%, 63%, and 29.4% [1]